SCHEMBL6511706

SCHEMBL6511706

C[C@@H](OC(=O)Nc1ccc(Cl)c(Cl)c1)c1nc2ccc3ccccc3c2[nH]1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.42
MAPT P10636 3/20 0.42
HTT P42858 2/20 0.42
MEN1 O00255 1/20 0.42
MAPK1 P28482 1/20 0.42
KMT2A Q03164 1/20 0.42
LMNA P02545 1/20 0.40
ESRRA P11474 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
SERPINE1 P05121 1/20 0.39
ADORA3 P0DMS8 1/20 0.38
HTR2B P41595 1/20 0.38
TMEM97 Q5BJF2 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
AGPAT2 O15120 2/20 0.37
GRM4 Q14833 1/20 0.37
HPGD P15428 1/20 0.37
ALOX15 P16050 1/20 0.37
DGAT1 O75907 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6511712 1.00 GRM5 (0.42) GRM5MAPTHTTMEN1MAPK1
SCHEMBL6515185 1.00 GRM5 (0.42) GRM5MAPTHTTMEN1MAPK1
SCHEMBL6513492 0.89 GRM5 (0.43) GRM5MAPTHTTMEN1MAPK1
SCHEMBL6513486 0.89 GRM5 (0.43) GRM5MAPTHTTMEN1MAPK1
SCHEMBL6512272 0.87 GRM5 (0.46) GRM5MAPTHTTMEN1MAPK1
SCHEMBL6512270 0.87 GRM5 (0.46) GRM5MAPTHTTMEN1MAPK1
SCHEMBL6511672 0.84 GRM5 (0.46) GRM5MAPTHTTMEN1MAPK1
SCHEMBL6511677 0.84 GRM5 (0.46) GRM5MAPTHTTMEN1MAPK1
SCHEMBL6510982 0.83 LMNA (0.51) GRM5MAPTHTTMEN1MAPK1
SCHEMBL6510975 0.83 LMNA (0.51) GRM5MAPTHTTMEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050148643-A1 Carbamate compositions and methods fo rmodulating the activity of the CHK1 enzyme AGOURON PHARMACEUTICALS, INC. 2005-07-07 US claimed
US-20050148643-A1 Carbamate compositions and methods fo rmodulating the activity of the CHK1 enzyme AGOURON PHARMACEUTICALS, INC. 2005-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148643-A1 Carbamate compositions and methods fo rmodulating the activity of the CHK1 enzyme CHEK1, CHEK2, RAD1 GRM5 4202/4885MAPT 3549/4885HTT 4339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.